Skip to main content
Exosla Limited on Muck Rack

Exosla Limited

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Exosla

Contact Exosla, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EV products obtained from iPSC-derived MSCs show batch-to-batch variations in their ability to modulate allogeneic immune responses in vitro

|
By Anna Meyfour, Yuyao Tian, Exosla Limited, Nasim Eslami
| Frontiers
Introduction Despite significant progress in science, the human society is still suffering from many diseases without having real cure options. Among them are many diseases whose symptomologies are closely associated with proinflammatory processes, ranging from early neonates, e.g., in hypoxia induced encephalopathy patients, to elder individuals suffering from a variety of different degenerative diseases or ischemia reperfusion injuries, including ischemic stroke and myocardial infarction.
Open in Who Shared Issue with article?
See all 1 articles